Sangamo Therapeutics Received U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

Click here to view

Presentation

Poster: Highly Specific Zinc Finger Proteins with Synthetic Target Sites Enable Self-Regulated Expression of Dosage-Sensitive Transgenes

Download PDF